The role of lncRNAs in regulation of DKD and diabetes-related cancer

Abstract

Diabetes mellitus often results in several complications, such as diabetic kidney disease (DKD) and end-stage renal diseases (ESRDs). Cancer patients often have the dysregulated glucose metabolism. Abnormal glucose metabolism can enhance the tumor malignant progression. Recently, lncRNAs have been reported to regulate the key proteins and signaling pathways in DKD development and progression and in cancer patients with diabetes. In this review article, we elaborate the evidence to support the function of lncRNAs in development of DKD and diabetes-associated cancer. Moreover, we envisage that lncRNAs could be diagnosis and prognosis biomarkers for DKD and cancer patients with diabetes. Furthermore, we delineated that targeting lncRNAs might be an alternative approach for treating DKD and cancer with dysregulated glucose metabolism.

The emerging role of lncRNAs in osteoarthritis development and potential therapy

“…It has been shown that miRNA can bind to specific mRNA molecules and cause the inhibition of translation or degradation, leading to regulation of gene expression. LncRNAs with longer than 200 nucleotides have been identified to involve in diverse diseases via regulating gene expression and chromatin remodeling, including cancer, neurodegenerative diseases and cardiovascular disorders ( Jiang et al, 2020 ; Cheng et al, 2022 ; Gareev et al, 2022 ; Sufianova et al, 2022 ; Xie et al, 2022 ). LncRNAs have gained significant attention and play crucial regulatory roles in osteoarthritis ( Chen et al, 2017 ; Abbasifard et al, 2020 ; Tu et al, 2020 ; Wang et al, 2022 ; Okuyan and Begen, 2022 ).…”